Perspectives on the recommendations for skin cancer management during the COVID-19 pandemic

J Am Acad Dermatol. 2020 Jul;83(1):295-296. doi: 10.1016/j.jaad.2020.05.002. Epub 2020 May 6.

Authors

Larisa J Geskin¹, Megan H Trager², Sumaira Z Aasi³, David R Bickers², Richard D Carvajal⁴, Paul Nghiem⁵, Bret Taback⁶, Nathalie C Zeitouni⁷, Faramarz H Samie²

Affiliations

¹ Department of Dermatology, Columbia University Irving Medical Center, New York, New York. Electronic address: ljg2145@cumc.columbia.edu.
² Department of Dermatology, Columbia University Irving Medical Center, New York, New York.
³ Department of Dermatology, Stanford Medicine, Stanford, California.
⁴ Division of Hematology, Department of Medicine, Columbia University Irving Medical Center, New York, New York.
⁵ Department of Dermatology, University of Washington Medical Center, Seattle, Washington.
⁶ Department of Surgery, Columbia University Irving Medical Center, New York, New York.
⁷ Department of Dermatology, University of Arizona College of Medicine, Phoenix, Arizona.

No abstract available

MeSH terms

Betacoronavirus / immunology
Betacoronavirus / pathogenicity*
COVID-19
Chemotherapy, Adjuvant / standards
Coronavirus Infections / epidemiology
Coronavirus Infections / prevention & control*
Coronavirus Infections / transmission
Coronavirus Infections / virology
Dermatology / methods
Dermatology / standards*
Humans
Immunotherapy / adverse effects
Immunotherapy / standards
Infection Control / standards
Infusions, Intravenous / standards
Medical Oncology / methods
Medical Oncology / standards*
Mohs Surgery / standards
Neoadjuvant Therapy / standards
Pandemics / prevention & control*
Pneumonia, Viral / epidemiology
Pneumonia, Viral / prevention & control*
Pneumonia, Viral / transmission
Pneumonia, Viral / virology
Risk Assessment / standards
SARS-CoV-2
Skin / pathology
Skin Neoplasms / immunology
Skin Neoplasms / pathology
Skin Neoplasms / therapy*
Telemedicine / standards

Grants and funding

P30 AR069632/AR/NIAMS NIH HHS/United States